Search Results

You are looking at 1 - 10 of 27 items for :

  • "raloxifene" x
  • Refine by Access: All x
Clear All
Full access

The STAR Trial: Evidence for Raloxifene as a Breast Cancer Risk Reduction Agent for Postmenopausal Women

Therese B. Bevers

– 5687 . 2. Lamb CA Helguero LA Fabris V . Differential effects of raloxifene, tamoxifen and fulvestrant on a murine mammary carcinoma . Breast Cancer Res Treat 2003 ; 79 : 25 – 35 . 3. Sporn MB Dowsett SA Mershon J Bryant HU

Full access

Breast Cancer Risk Reduction

Therese B. Bevers, Deborah K. Armstrong, Banu Arun, Robert W. Carlson, Kenneth H. Cowan, Mary B. Daly, Irvin Fleming, Judy E. Garber, Mary Gemignani, William J. Gradishar, Helen Krontiras, Swati Kulkarni, Christine Laronga, Loretta Loftus, Deborah J. MacDonald, Martin C. Mahoney, Sofia D. Merajver, Ingrid Meszoely, Lisa Newman, Elizabeth Pritchard, Victoria Seewaldt, Rena V. Sellin, Charles L. Shapiro, and John H. Ward

reduction agents/strategies, such as tamoxifen, raloxifene, and risk reduction surgery, have been identified. However, women and their physicians who are considering interventions to reduce risk for breast cancer must balance the demonstrated benefits with

Full access

Nonhormonal Management of Hot Flashes for Women on Risk Reduction Therapy

Kostandinos Sideras and Charles L. Loprinzi

cancer risk reduction be discussed and considered as an option for women with increased risk of developing breast cancer. 6 , 7 For postmenopausal women, the currently approved agents are tamoxifen and raloxifene, both recommended for a maximum of 5

Full access

Breast Cancer Risk Reduction and Counseling: Lifestyle, Chemoprevention, and Surgery

Martin C. Mahoney

Project P-1 Study . J Natl Cancer Inst 1998 ; 90 : 1371 – 1388 . 23. Vogel VG Costantino JP Wickerham DL . Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of

Full access

Barriers to the Use of Breast Cancer Risk Reduction Therapies

Arvind Bambhroliya, Mariana Chavez-MacGregor, and Abenaa M. Brewster

trials of tamoxifen compared with placebo demonstrated a more modest benefit of tamoxifen (39%–22%) for reducing the risk of ER-positive tumors. 2 – 4 The initial results of the Study of Tamoxifen and Raloxifene (STAR) trial after 47 months of follow

Full access

Breast Risk Reduction

Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Breast cancer is the most commonly diagnosed cancer in American women, with an estimated 214,640 cases and 41,430 deaths occurring in 2006. Estimating breast cancer risk for individual women is difficult, and most breast cancers are not attributable to risk factors other than female gender and increased age. Developing effective strategies for reducing breast cancer incidence is also difficult because few existing risk factors are modifiable and some potentially modifiable risk factors have social implications. Nevertheless, effective breast cancer risk reduction agents and strategies, such as tamoxifen, raloxifene, and risk reduction surgery, have been identified. These guidelines were developed to help women at increased risk for breast cancer and their physicians apply individualized strategies to reduce breast cancer risk.

For the most recent version of the guidelines, please visit

Full access

Breast Cancer Risk Reduction Therapy: The Low-Hanging Fruit

Therese B. Bevers

More than 15 years ago, tamoxifen was FDA-approved for breast cancer risk reduction in women at an increased risk of developing breast cancer. Since that time, raloxifene has also received FDA approval for this purpose. Both of these drugs halve

Full access

Breast Cancer Risk Reduction, Version 2.2015

Therese B. Bevers, John H. Ward, Banu K. Arun, Graham A. Colditz, Kenneth H. Cowan, Mary B. Daly, Judy E. Garber, Mary L. Gemignani, William J. Gradishar, Judith A. Jordan, Larissa A. Korde, Nicole Kounalakis, Helen Krontiras, Shicha Kumar, Allison Kurian, Christine Laronga, Rachel M. Layman, Loretta S. Loftus, Martin C. Mahoney, Sofia D. Merajver, Ingrid M. Meszoely, Joanne Mortimer, Lisa Newman, Elizabeth Pritchard, Sandhya Pruthi, Victoria Seewaldt, Michelle C. Specht, Kala Visvanathan, Anne Wallace, Mary Ann Bergman, and Rashmi Kumar

-year actuarial breast cancer risk as defined by the modified Gail model, which was used to identify women eligible for the NSABP Breast Cancer Prevention Trial (BCPT) 72 , 73 and the Study of Tamoxifen and Raloxifene (STAR) trial. 74 , 75 The Gail

Full access

NCCN Task Force Report: Bone Health in Cancer Care

Julie R. Gralow, J. Sybil Biermann, Azeez Farooki, Monica N. Fornier, Robert F. Gagel, Rashmi N. Kumar, Charles L. Shapiro, Andrew Shields, Matthew R. Smith, Sandy Srinivas, and Catherine H. Van Poznak

postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators . JAMA 1999 ; 282 : 637 – 645 . 66 Barrett-Connor E Mosca L Collins P

Full access

Patients and Clinical Practice Guidelines Development

Rodger J. Winn . 16 Chlebowski RT Col N Winer EP . American Society of Clinical Oncology Technology Assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition . J Clin Oncol 2002 ; 20